Concepedia

Author

Yi Wang

Huaian First People’s HospitalORCID

Also Known As

Wang, Yi, Y Wang, Yi Wang

23

Publications

237

Citations

9

H-Index

11

Concepts

All Affiliations

Huaian First People’s HospitalMitsubishi Corporation (United States)Peking University People's HospitalPeking University
YW

About

Yi Wang is an author at Huaian First People’s Hospital specializing in cellular biochemistry, drug discovery, and molecular pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

13

2

Natural Sciences

1

1

13

3

Biochemistry

1

1

13

4

Cell Biology

1

1

13

5

Pharmacology

1

1

13

Yi Wang

×

8

Publications

201

Citations

8

H-Index

YearCitations

Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure

Rudolf A. de Boer, Julio Núñez, Plamen Kozlovski,

British Journal of Clinical Pharmacology

2020

63

Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.

Yong Zhou, Weiwei Ye, Yi Wang,

PubMed

2015

49

Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis

Yi Wang, Yan‐Hui Liu, Shi‐Juan Mai,

Journal of Gastroenterology and Hepatology

2009

28

<scp> Na <sup>+</sup> /H <sup>+</sup> </scp> exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium‐glucose co‐transporter 1‐mediated glucose absorption in the small intestine

Leo Chan, Yi Wang, Enders K. Ng,

Diabetes Obesity and Metabolism

2017

14

The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway

Shumin Jiang, Xueli Wu, Yi Wang,

European Journal of Pharmacology

2020

13

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Linong Ji, Ling Li, Jianhua Ma,

Endocrinology Diabetes & Metabolism

2021

13

Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice

Leping Zhao, Yong Pan, Kesong Peng,

Journal of Molecular Endocrinology

2015

11

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Linong Ji, Jianhua Ma, Weiping Lu,

Journal of Diabetes Investigation

2020

10

Page 1